News

TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites

CNS’ licensing agreement with HPI grants the Company the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer globally. In its agreement

Daratumumab is a first-in-class biologic designed to target CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage. Daratumumab is considered to

In this regard, the companies will make use of GalXC, an RNA interference (RNAi) technology platform developed by Dicerna, for the discovery of new therapies. The collaboration will

“Biosimilars like ABRILADA represent an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions,” said Richard Blackburn, Global

AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The active ingredient in AVX-012 is a potent and

As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion of the deal. Rodin is also eligible to

Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with sickle cell disease, aged 16

In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results